Related Experiment Videos
Nasal mupirocin treatment of pharynx-colonized methicillin resistant Staphylococcus aureus: preliminary study with 10
T Hayakawa1, T Hayashidera, S Katsura
1Department of Pediatrics, Kyoto National Hospital, Japan.
Background:
Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection in infants has become a serious concern and a new means of preventing the transmission of MRSA in the community needs to be considered.
Methods:
We performed nasal mupirocin treatment on 10 infants who were MRSA-positive either in the nose or the pharynx and evaluated the effect of mupirocin on the eradication of MRSA.
Results:
Eradication of MRSA from the nose was successful in two cases and eradication from the pharynx in six (66.6%) of nine cases. The number of treatments required to achieve eradication varied; within three courses for nose carriers and from one to seven courses for pharynx carriers. Eradication was unsuccessful even after five to seven treatments in three pharynx-limited carriers.
Conclusions:
These data suggest that the effect of nasal mupirocin treatment on pharynx-colonized MRSA is limited and that repetitive treatment is necessary in some cases. However, in view of the possibility of preferential pharyngeal colonization of Staphylococcus aureus in infancy, nasal mupirocin treatment deserves further evaluation for eradication not only of nose- but also of pharynx-colonized MRSA.
Insights
Nasal mupirocin treatment showed limited success in eradicating methicillin-resistant Staphylococcus aureus (MRSA) from infants' pharynx. Further evaluation is needed for effective MRSA prevention in this vulnerable population.
Area of Science:
- Pediatric Infectious Diseases
- Microbiology
- Public Health
Background:
- Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infections in infants pose a significant public health challenge.
- Preventing MRSA transmission in community settings is crucial.
Purpose of the Study:
- To evaluate the efficacy of nasal mupirocin treatment for MRSA eradication in infants.
- To assess MRSA clearance from both nasal and pharyngeal sites.
Main Methods:
- Ten MRSA-positive infants (nasal or pharyngeal carriage) received nasal mupirocin treatment.
- The study monitored MRSA eradication rates and the number of treatment courses required.
Main Results:
- Successful MRSA eradication from the nose occurred in 2 out of 10 infants.
- Pharyngeal MRSA eradication was achieved in 66.6% (6/9) of cases.
- Eradication required 1-7 courses, with 3 pharyngeal carriers remaining positive after 5-7 treatments.
Conclusions:
- Nasal mupirocin has limited efficacy for pharyngeal MRSA eradication in infants.
- Repetitive treatments may be necessary for some infants.
- Further research on nasal mupirocin for both nasal and pharyngeal MRSA in infants is warranted.